PRKAR1B and neoplasm: Administration of DOPC-PRKAR1B-AS2-siRNA + cisplatin significantly decreased tumor weight by 74% (p = 0.03) compared with PRKAR1B-AS2-siRNA alone and by 67% (p = 0.018) compared with DOPC-negative control siRNA + cisplatin (Figure 6A).